News articles about Quidel (NASDAQ:QDEL) have trended somewhat positive on Friday, according to Accern. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quidel earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0597452557768 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Several research firms recently weighed in on QDEL. BidaskClub lowered Quidel from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Piper Jaffray Companies restated a “buy” rating and set a $60.00 price target on shares of Quidel in a research report on Wednesday, January 24th. Barclays lifted their price target on Quidel from $50.00 to $60.00 and gave the company an “overweight” rating in a research report on Monday, January 22nd. CL King upgraded Quidel from a “neutral” rating to a “buy” rating and set a $52.00 price target on the stock in a research report on Thursday, January 4th. Finally, Zacks Investment Research downgraded Quidel from a “hold” rating to a “strong sell” rating in a report on Thursday, December 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $53.50.
Quidel (QDEL) traded up $0.77 during trading on Friday, reaching $45.87. The company’s stock had a trading volume of 191,954 shares, compared to its average volume of 315,962. The company has a quick ratio of 5.68, a current ratio of 6.28 and a debt-to-equity ratio of 0.70. Quidel has a twelve month low of $20.43 and a twelve month high of $49.47. The company has a market capitalization of $1,560.00, a P/E ratio of -286.13, a price-to-earnings-growth ratio of 1.41 and a beta of 1.02.
In other Quidel news, CEO Douglas C. Bryant sold 12,000 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $46.82, for a total value of $561,840.00. Following the sale, the chief executive officer now directly owns 286,493 shares of the company’s stock, valued at $13,413,602.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Douglas C. Bryant sold 36,000 shares of the business’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $37.36, for a total value of $1,344,960.00. Following the completion of the transaction, the chief executive officer now owns 296,493 shares of the company’s stock, valued at approximately $11,076,978.48. The disclosure for this sale can be found here. Insiders sold 370,260 shares of company stock worth $15,293,980 over the last three months. Corporate insiders own 22.00% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/16/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-quidel-qdel-stock-price.html.
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.